Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions

Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions

New therapies are needed to improve survival for patients with Ewing sarcoma. Over the past decade, camptothecin agents such as topotecan and irinotecan have demonstrated activity against Ewing sarcoma, especially in combination with alkylating agents. Previous studies have shown camptothecin-based...

Full description

Bibliographic Details
Main Author: Lars Wagner
Format: Article
Language:English
Published: Hindawi Limited 2011-01-01
Series:Sarcoma
Online Access:http://dx.doi.org/10.1155/2011/957957
id doaj-59154e9340044abf8d7d43b37d7bb1a3
record_format Article
spelling doaj-59154e9340044abf8d7d43b37d7bb1a32020-11-24T23:20:42ZengHindawi LimitedSarcoma1357-714X1369-16432011-01-01201110.1155/2011/957957957957Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future DirectionsLars Wagner0Division of Pediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, MLC 7015, 3333 Burnet Avenue, Cincinnati, OH 45229, USANew therapies are needed to improve survival for patients with Ewing sarcoma. Over the past decade, camptothecin agents such as topotecan and irinotecan have demonstrated activity against Ewing sarcoma, especially in combination with alkylating agents. Previous studies have shown camptothecin-based combinations to be tolerable outpatient strategies that are attractive for salvage therapy. This paper highlights important issues related to drug dosing, schedule of administration, pharmacokinetics, toxicity, and activity of commonly used camptothecin-based regimens. Also discussed are strategies for incorporating these regimens into therapy for newly diagnosed patients, including several potential possibilities for combination with targeted agents.http://dx.doi.org/10.1155/2011/957957
collection DOAJ
language English
format Article
sources DOAJ
author Lars Wagner
spellingShingle Lars Wagner
Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions
Sarcoma
author_facet Lars Wagner
author_sort Lars Wagner
title Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions
title_short Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions
title_full Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions
title_fullStr Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions
title_full_unstemmed Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions
title_sort camptothecin-based regimens for treatment of ewing sarcoma: spast studies and future directions
publisher Hindawi Limited
series Sarcoma
issn 1357-714X
1369-1643
publishDate 2011-01-01
description New therapies are needed to improve survival for patients with Ewing sarcoma. Over the past decade, camptothecin agents such as topotecan and irinotecan have demonstrated activity against Ewing sarcoma, especially in combination with alkylating agents. Previous studies have shown camptothecin-based combinations to be tolerable outpatient strategies that are attractive for salvage therapy. This paper highlights important issues related to drug dosing, schedule of administration, pharmacokinetics, toxicity, and activity of commonly used camptothecin-based regimens. Also discussed are strategies for incorporating these regimens into therapy for newly diagnosed patients, including several potential possibilities for combination with targeted agents.
url http://dx.doi.org/10.1155/2011/957957
work_keys_str_mv AT larswagner camptothecinbasedregimensfortreatmentofewingsarcomaspaststudiesandfuturedirections
_version_ 1725574051788750848

Similar Items